Biosimilars back on the radar for 2023. Expect to see 17 in rheum. #RNL2023 @RheumNow https://t.co/SNYNM8nmD2

Biosimilar to biosimilar switching of Infliximab , ⁦@RheumNow⁩ Kavanaugh #RNL2023 Communications is a key always. Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ

Will be begin using sputum instead of blood serologies to detect RA? - sputum seropositive CCP may be associated with development of clinical RA - 4 fold higher risk if (induced) sputum CCP+ @RheumNow #RNL2023 https://t.co/Z85GDwIyl8

#RNL2023 Year in Review Sputum antibody predicts future development of RA Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA) Strongest association with CCP IgA Supports pre-RA as mucosal disease @RheumNow https://t.co/Js4JPZiLDB

How does HCQ work @Lupusreference in #RNL2023 HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN HCQ works as base to increase lysosomal pH and affect cellular function @RheumNow https://t.co/RTEUF0cS0u

@Lupusreference in #RNL2023 HCQ and arrhythmia via QTc prolongation At normal doses, same as general population If on other QTc prolonging medications, a baseline EKG may be beneficial @RheumNow https://t.co/cAN2vBNa1t

Any dose more than 1500 is associated with retinopathy ? So what to do. ⁦@Lupusreference⁩ #RNL2023 ⁦@RheumNow⁩ https://t.co/2zdjpcuvKa

Smoking and SLE Smoking increases SLE activity Smoking decreases HCQ efficacy Skin response on HCQ down 50% in smokers 🚬 @Lupusreference #RNL2023 @RheumNow

TULIP trials in lupus, disease outcomes and others, by Richard Furie #RNL2023 ⁦@RheumNow⁩ https://t.co/uUQOxUIzJN

Dr. Furie: #RNL2023 Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature @RheumNow https://t.co/30oFRwwuTG

✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023 @RheumNow ⬇️ https://t.co/E2xdv3ODG6

SRI Responders more likely able to reduce prednisone and far Serological improvement SF-36 Fatigue by Richard Furie #RNL2023 ⁦@RheumNow⁩ https://t.co/ilsyOXw7nA

Compliance is always an issue, by Richard Furie #RNL2023 ⁦@RheumNow⁩ . Plaquenil level were below target. Adherence is always something we need to work on. https://t.co/hMgL9kY0rZ

Dr. Ken Kalunian on Lupus nephritis Don't forget about ACEi/ARB therapy for SLE pts with renal involvement - can control BP - reduce Urine proteinuria - decrease risk of active renal disease #RNL2023 @RheumNow https://t.co/hLBqjELqW2

UPCR< 500 mg is the best predictor of a renal outcome in lupus nephritis. Multiple creatinine testing, Ken Kalunian #RNL2023 ⁦@RheumNow⁩ https://t.co/96PlXgqOfK